{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:56:17Z","timestamp":1791240977107,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Claudin 18.2 (CLDN18.2)-targeted CAR-T cell and antibody therapies show promise against gastrointestinal cancers, but biomarkers predictive of long-term benefit and therapeutic sensitization strategies are needed. Here we show that proteins carried by circulating extracellular vesicles (EVs) can reflect and influence the efficacy of CLDN18.2-targeted therapies. By profiling serial plasma samples of patients from the CT041-CG4006 trial (CLDN18.2- CAR-T-therapy) or the GLOW trial (Zolbetuximab), we identified EV-associated CLDN18.2, PD1 and PD-L2 as therapeutic markers and integrated them into a signature (CPP-score) for better predictive robustness. Mechanistically, specific EV-proteins exhaust CAR-T cells, neutralize CLDN18.2-targeted-antibodies, activate immunosuppressive IL-6-expressing cancer-associated fibroblasts, and alter the TH1\/TH2 balance, thereby reshaping the tumor microenvironment and interfere with CLDN18.2-targeted therapies. Strategies including combining anti-PD1 antibody or CAF inhibitor, CLDN18.2-CAR-T plus CLDN18.2-antibody, and depleting plasma EVs, can sensitize CLDN18.2-CAR-T\/antibody by countermeasuring EV-proteins\u2019 therapeutic interferences. Collectively, our work provides potential options to monitor and improve CLDN18.2-targeted therapies in clinical practice.<\/jats:p>","DOI":"10.1038\/s41467-026-77132-9","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:25:27Z","timestamp":1788452727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Extracellular vesicle proteins monitor and interfere with CLDN18.2-targeted CAR-T cell and antibody therapies against gastrointestinal cancers"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9157-3768","authenticated-orcid":false,"given":"Changsong","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijie","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9388-4180","authenticated-orcid":false,"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9340-3962","authenticated-orcid":false,"given":"Jiarui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangli","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengde","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zizhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congcong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuezong","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7634-8471","authenticated-orcid":false,"given":"Chuanhui","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6936-2622","authenticated-orcid":false,"given":"Xiaotian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3798-7024","authenticated-orcid":false,"given":"Jifang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9333-3255","authenticated-orcid":false,"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1134-2922","authenticated-orcid":false,"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1290-8855","authenticated-orcid":false,"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"77132_CR1","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin, U. et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin. Cancer Res. 14, 7624\u20137634, https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1547 (2008).","journal-title":"Clin. Cancer Res."},{"key":"77132_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.gene.2011.04.007","volume":"481","author":"O Tureci","year":"2011","unstructured":"Tureci, O. et al. Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene 481, 83\u201392, https:\/\/doi.org\/10.1016\/j.gene.2011.04.007 (2011).","journal-title":"Gene"},{"key":"77132_CR3","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1523096","volume":"8","author":"\u04e6 Tureci","year":"2019","unstructured":"Tureci, \u04e6, Mitnacht-Kraus, R., Woll, S., Yamada, T. & Sahin, U. Characterization of zolbetuximab in pancreatic cancer models. Oncoimmunology 8, e1523096. https:\/\/doi.org\/10.1080\/2162402X.2018.1523096 (2019).","journal-title":"Oncoimmunology"},{"key":"77132_CR4","doi-asserted-by":"publisher","unstructured":"Nakayama, I. et al. Claudin 18.2 as a novel therapeutic target. Nat. Rev. Clin. Oncol. https:\/\/doi.org\/10.1038\/s41571-024-00874-2 (2024).","DOI":"10.1038\/s41571-024-00874-2"},{"key":"77132_CR5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/d41573-021-00031-9","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard, A. FDA approves fourth CAR-T cell therapy. Nat. Rev. Drug Discov. 20, 166, https:\/\/doi.org\/10.1038\/d41573-021-00031-9 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"77132_CR6","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28, 1189\u20131198, https:\/\/doi.org\/10.1038\/s41591-022-01800-8 (2022).","journal-title":"Nat. Med."},{"key":"77132_CR7","doi-asserted-by":"publisher","unstructured":"Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-024-03037-z (2024).","DOI":"10.1038\/s41591-024-03037-z"},{"key":"77132_CR8","doi-asserted-by":"publisher","unstructured":"Qi, C. et al. Safety and efficacy of CT041 in patients with refractory metastatic pancreatic cancer: a pooled analysis of two early-phase trials. J. Clin. Oncol, JCO2302314, https:\/\/doi.org\/10.1200\/JCO.23.02314 (2024).","DOI":"10.1200\/JCO.23.02314"},{"key":"77132_CR9","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","volume":"405","author":"C Qi","year":"2025","unstructured":"Qi, C. et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet 405, 2049\u20132060, https:\/\/doi.org\/10.1016\/S0140-6736(25)00860-8 (2025).","journal-title":"Lancet"},{"key":"77132_CR10","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara, K. et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401, 1655\u20131668, https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7 (2023).","journal-title":"Lancet"},{"key":"77132_CR11","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah, M. A. et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat. Med. 29, 2133\u20132141, https:\/\/doi.org\/10.1038\/s41591-023-02465-7 (2023).","journal-title":"Nat. Med."},{"key":"77132_CR12","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1056\/NEJMc2409512","volume":"391","author":"K Shitara","year":"2024","unstructured":"Shitara, K. et al. Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma. N. Engl. J. Med. 391, 1159\u20131162, https:\/\/doi.org\/10.1056\/NEJMc2409512 (2024).","journal-title":"N. Engl. J. Med."},{"key":"77132_CR13","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.cell.2023.03.010","volume":"186","author":"R Kalluri","year":"2023","unstructured":"Kalluri, R. & McAndrews, K. M. The role of extracellular vesicles in cancer. Cell 186, 1610\u20131626, https:\/\/doi.org\/10.1016\/j.cell.2023.03.010 (2023).","journal-title":"Cell"},{"key":"77132_CR14","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.cell.2020.07.009","volume":"182","author":"A Hoshino","year":"2020","unstructured":"Hoshino, A. et al. Extracellular vesicle and particle biomarkers define multiple human cancers. Cell 182, 1044\u20131061 e1018, https:\/\/doi.org\/10.1016\/j.cell.2020.07.009 (2020).","journal-title":"Cell"},{"key":"77132_CR15","doi-asserted-by":"publisher","unstructured":"Jorgensen, M. et al. Extracellular Vesicle (EV) Array: microarray capturing of exosomes and other extracellular vesicles for multiplexed phenotyping. J. Extracell Vesicles 2, https:\/\/doi.org\/10.3402\/jev.v2i0.20920 (2013).","DOI":"10.3402\/jev.v2i0.20920"},{"key":"77132_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-02301406-8","volume":"22","author":"S Liu","year":"2024","unstructured":"Liu, S. et al. Claudin-18.2 mediated interaction of gastric cancer cells and cancer-associated fibroblasts drives tumor progression. Cell Commun. Signal 22, 27. https:\/\/doi.org\/10.1186\/s12964-02301406-8 (2024).","journal-title":"Cell Commun. Signal"},{"key":"77132_CR17","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41590-018-0207-y","volume":"19","author":"D Huang","year":"2018","unstructured":"Huang, D. et al. NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nat. Immunol. 19, 1112\u20131125, https:\/\/doi.org\/10.1038\/s41590-018-0207-y (2018).","journal-title":"Nat. Immunol."},{"key":"77132_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12209","volume":"11","author":"C Zhang","year":"2022","unstructured":"Zhang, C. et al. Plasma extracellular vesicle derived protein profile predicting and monitoring immunotherapeutic outcomes of gastric cancer. J. Extracell. Vesicles 11, e12209. https:\/\/doi.org\/10.1002\/jev2.12209 (2022).","journal-title":"J. Extracell. Vesicles"},{"key":"77132_CR19","doi-asserted-by":"publisher","unstructured":"Zhou, W. et al. Microwave ablation induces Th1-type immune response with activation of ICOS pathway in early-stage breast cancer. J. Immunother. Cancer 9, https:\/\/doi.org\/10.1136\/jitc-2021-002343 (2021).","DOI":"10.1136\/jitc-2021-002343"},{"key":"77132_CR20","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41590-021-00899-0","volume":"22","author":"C Marar","year":"2021","unstructured":"Marar, C., Starich, B. & Wirtz, D. Extracellular vesicles in immunomodulation and tumor progression. Nat. Immunol. 22, 560\u2013570, https:\/\/doi.org\/10.1038\/s41590-021-00899-0 (2021).","journal-title":"Nat. Immunol."},{"key":"77132_CR21","doi-asserted-by":"crossref","unstructured":"Mondal, S. K., Haas, D. A.-O., Han, J. & Whiteside, T. A.-O. Small EV in plasma of triple negative breast cancer patients induce intrinsic apoptosis in activated T cells. Commun. Biol. 6, 815 (2023).","DOI":"10.1038\/s42003-023-05169-3"},{"key":"77132_CR22","doi-asserted-by":"crossref","unstructured":"Semionatto, I. F. et al. Extracellular vesicles produced by immunomodulatory cells harboring OX40 ligand and 4-1BB ligand enhance antitumor immunity. Sci. Rep. 10, 15160 (2020).","DOI":"10.1038\/s41598-020-72122-3"},{"key":"77132_CR23","doi-asserted-by":"publisher","unstructured":"Wortzel, I. et al. Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression. Nat Cancer https:\/\/doi.org\/10.1038\/s43018-024-00862-6 (2024).","DOI":"10.1038\/s43018-024-00862-6"},{"key":"77132_CR24","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.210276","volume":"11","author":"A Tsakaneli","year":"2021","unstructured":"Tsakaneli, A. et al. MYC regulates metabolism through vesicular transfer of glycolytic kinases. Open Biol. 11, 210276. https:\/\/doi.org\/10.1098\/rsob.210276 (2021).","journal-title":"Open Biol."},{"key":"77132_CR25","first-page":"2521","volume":"35","author":"BH Haug","year":"2015","unstructured":"Haug, B. H. et al. Exosome-like extracellular vesicles from MYCN-amplified neuroblastoma cells contain oncogenic miRNAs. Anticancer Res 35, 2521\u20132530 (2015).","journal-title":"Anticancer Res"},{"key":"77132_CR26","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/j.devcel.2021.05.014","volume":"56","author":"S Kilinc","year":"2021","unstructured":"Kilinc, S. et al. Oncogene-regulated release of extracellular vesicles. Dev. Cell 56, 1989\u20132006 e1986, https:\/\/doi.org\/10.1016\/j.devcel.2021.05.014 (2021).","journal-title":"Dev. Cell"},{"key":"77132_CR27","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ccell.2024.01.002","volume":"42","author":"DD Klysz","year":"2024","unstructured":"Klysz, D. D. et al. Inosine induces stemness features in CAR-T cells and enhances potency. Cancer Cell 42, 266\u2013282 e268, https:\/\/doi.org\/10.1016\/j.ccell.2024.01.002 (2024).","journal-title":"Cancer Cell"},{"key":"77132_CR28","doi-asserted-by":"publisher","unstructured":"Majumder, A. Evolving CAR-T-cell therapy for cancer treatment: from scientific discovery to cures. Cancers 16, https:\/\/doi.org\/10.3390\/cancers16010039 (2023).","DOI":"10.3390\/cancers16010039"},{"key":"77132_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-27604-5","volume":"13","author":"VM Ukrainskaya","year":"2023","unstructured":"Ukrainskaya, V. M. et al. CAR-tropic extracellular vesicles carry tumor-associated antigens and modulate CAR T cell functionality. Sci. Rep. 13, 463. https:\/\/doi.org\/10.1038\/s41598-023-27604-5 (2023).","journal-title":"Sci. Rep."},{"key":"77132_CR30","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.ymthe.2020.12.033","volume":"29","author":"MJ Cox","year":"2021","unstructured":"Cox, M. J. et al. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia. Mol. Ther. 29, 1529\u20131540, https:\/\/doi.org\/10.1016\/j.ymthe.2020.12.033 (2021).","journal-title":"Mol. Ther."},{"key":"77132_CR31","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1158\/0008-5472.CAN-22-2220","volume":"83","author":"W Zhong","year":"2023","unstructured":"Zhong, W. et al. Tumor-derived small extracellular vesicles inhibit the efficacy of CAR T cells against solid tumors. Cancer Res. 83, 2790\u20132806, https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-2220 (2023).","journal-title":"Cancer Res."},{"key":"77132_CR32","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1016\/j.cell.2021.08.004","volume":"184","author":"LR Johnson","year":"2021","unstructured":"Johnson, L. R. et al. The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function. Cell 184, 4981\u20134995, https:\/\/doi.org\/10.1016\/j.cell.2021.08.004 (2021).","journal-title":"Cell"},{"key":"77132_CR33","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/jcp.22773","volume":"227","author":"V Ciravolo","year":"2012","unstructured":"Ciravolo, V. et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J. Cell Physiol. 227, 658\u2013667, https:\/\/doi.org\/10.1002\/jcp.22773 (2012).","journal-title":"J. Cell Physiol."},{"key":"77132_CR34","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1146\/annurev-immunol-103019-085803","volume":"38","author":"M Ruterbusch","year":"2020","unstructured":"Ruterbusch, M., Pruner, K. B., Shehata, L. & Pepper, M. In vivo CD4(+) T cell differentiation and function: revisiting the Th1\/Th2 paradigm. Annu. Rev. Immunol. 38, 705\u2013725, https:\/\/doi.org\/10.1146\/annurev-immunol-103019-085803 (2020).","journal-title":"Annu. Rev. Immunol."},{"key":"77132_CR35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","volume":"18","author":"X Chen","year":"2019","unstructured":"Chen, X. & Song, E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat. Rev. Drug Discov. 18, 99\u2013115, https:\/\/doi.org\/10.1038\/s41573-018-0004-1 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"77132_CR36","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.trecan.2023.01.007","volume":"9","author":"L Arpinati","year":"2023","unstructured":"Arpinati, L. & Scherz-Shouval, R. From gatekeepers to providers: regulation of immune functions by cancer-associated fibroblasts. Trends Cancer 9, 421\u2013443, https:\/\/doi.org\/10.1016\/j.trecan.2023.01.007 (2023).","journal-title":"Trends Cancer"},{"key":"77132_CR37","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","volume":"18","author":"Y Chen","year":"2021","unstructured":"Chen, Y., McAndrews, K. M. & Kalluri, R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat. Rev. Clin. Oncol. 18, 792\u2013804, https:\/\/doi.org\/10.1038\/s41571-021-00546-5 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"77132_CR38","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","volume":"23","author":"S Rose-John","year":"2023","unstructured":"Rose-John, S., Jenkins, B. J., Garbers, C., Moll, J. M. & Scheller, J. Targeting IL-6 trans-signalling: past, present and future prospects. Nat. Rev. Immunol. 23, 666\u2013681, https:\/\/doi.org\/10.1038\/s41577-023-00856-y (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"77132_CR39","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.jtho.2016.05.025","volume":"11","author":"Y Shintani","year":"2016","unstructured":"Shintani, Y. et al. IL-6 secreted from cancer-associated fibroblasts mediates chemoresistance in NSCLC by increasing epithelial-mesenchymal transition signaling. J. Thorac. Oncol. 11, 1482\u20131492, https:\/\/doi.org\/10.1016\/j.jtho.2016.05.025 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"77132_CR40","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.1158\/10780432.CCR-18-0205","volume":"24","author":"T Kato","year":"2018","unstructured":"Kato, T. et al. Cancer-associated fibroblasts affect intratumoral CD8(+) and FoxP3(+) T cells via IL6 in the tumor microenvironment. Clin. Cancer Res. 24, 4820\u20134833, https:\/\/doi.org\/10.1158\/10780432.CCR-18-0205 (2018).","journal-title":"Clin. Cancer Res."},{"key":"77132_CR41","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","volume":"19","author":"DJ Propper","year":"2022","unstructured":"Propper, D. J. & Balkwill, F. R. Harnessing cytokines and chemokines for cancer therapy. Nat. Rev. Clin. Oncol. 19, 237\u2013253, https:\/\/doi.org\/10.1038\/s41571-021-00588-9 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"77132_CR42","doi-asserted-by":"publisher","unstructured":"Laino, A. S. et al. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J. Immunother. Cancer 8, https:\/\/doi.org\/10.1136\/jitc-2020-000842 (2020).","DOI":"10.1136\/jitc-2020-000842"},{"key":"77132_CR43","doi-asserted-by":"publisher","unstructured":"Keegan, A. et al. Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. J. Immunother. Cancer 8, https:\/\/doi.org\/10.1136\/jitc-2020-000678 (2020).","DOI":"10.1136\/jitc-2020-000678"},{"key":"77132_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02356-7","volume":"20","author":"C Liu","year":"2022","unstructured":"Liu, C. et al. Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer. BMC Med. 20, 187. https:\/\/doi.org\/10.1186\/s12916-022-02356-7 (2022).","journal-title":"BMC Med."},{"key":"77132_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100878","volume":"4","author":"MA Huseni","year":"2023","unstructured":"Huseni, M. A. et al. CD8(+) T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Rep. Med. 4, 100878. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100878 (2023).","journal-title":"Cell Rep. Med."},{"key":"77132_CR46","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/cac2.12452","volume":"43","author":"Y Qiao","year":"2023","unstructured":"Qiao, Y. et al. Enhancement of CAR-T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins. Cancer Commun. 43, 788\u2013807, https:\/\/doi.org\/10.1002\/cac2.12452 (2023).","journal-title":"Cancer Commun."},{"key":"77132_CR47","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","volume":"26","author":"KA Schalper","year":"2020","unstructured":"Schalper, K. A. et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat. Med. 26, 688\u2013692, https:\/\/doi.org\/10.1038\/s41591-020-0856-x (2020).","journal-title":"Nat. Med."},{"key":"77132_CR48","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41586-022-05272-1","volume":"611","author":"AT Krishnamurty","year":"2022","unstructured":"Krishnamurty, A. T. et al. LRRC15(+) myofibroblasts dictate the stromal setpoint to suppress tumour immunity. Nature 611, 148\u2013154, https:\/\/doi.org\/10.1038\/s41586-022-05272-1 (2022).","journal-title":"Nature"},{"key":"77132_CR49","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1158\/2159-8290.CD-19-1384","volume":"10","author":"Y Kieffer","year":"2020","unstructured":"Kieffer, Y. et al. Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov. 10, 1330\u20131351, https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1384 (2020).","journal-title":"Cancer Discov."},{"key":"77132_CR50","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/ajh.20342","volume":"79","author":"S Shariatmadar","year":"2005","unstructured":"Shariatmadar, S., Nassiri, M. & Vincek, V. Effect of plasma exchange on cytokines measured by multianalyte bead array in thrombotic thrombocytopenic purpura. Am. J. Hematol. 79, 83\u201388, https:\/\/doi.org\/10.1002\/ajh.20342 (2005).","journal-title":"Am. J. Hematol."},{"key":"77132_CR51","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1097\/LVT.0000000000000147","volume":"29","author":"N Oh","year":"2023","unstructured":"Oh, N. et al. Improved recurrence-free survival in patients with HCC with post-transplant plasma exchange. Liver Transpl. 29, 804\u2013812, https:\/\/doi.org\/10.1097\/LVT.0000000000000147 (2023).","journal-title":"Liver Transpl."},{"key":"77132_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.8124","volume":"11","author":"M Stortz","year":"2023","unstructured":"Stortz, M. et al. Plasma exchange for treatment of a therapy-related thrombotic microangiopathy in a patient with advanced hepatocellular carcinoma-A case report. Clin. Case Rep. 11, e8124. https:\/\/doi.org\/10.1002\/ccr3.8124 (2023).","journal-title":"Clin. Case Rep."},{"key":"77132_CR53","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami, H. et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel Plus S\u22121 versus cisplatin plus S\u22121 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J. Clin. Oncol. 36, 1922\u20131929, https:\/\/doi.org\/10.1200\/JCO.2018.77.8613 (2018).","journal-title":"J. Clin. Oncol."},{"key":"77132_CR54","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.18.01688","volume":"37","author":"PE Bonnot","year":"2019","unstructured":"Bonnot, P. E. et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J. Clin. Oncol. 37, 2028\u20132040, https:\/\/doi.org\/10.1200\/JCO.18.01688 (2019).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77132-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77132-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77132-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:35:40Z","timestamp":1791239740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77132-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77132"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77132-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"15 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Lin Shen received research fundings from BeiGene. Jian Li received a research funding from CARsgen Therapeutics Co., Ltd. Lin Shen, Cheng Zhang, Mingyang Ma, Changsong Qi, Jian Li and Jifang Gong applied a patent from China National Intellectual Property Administration. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10502"}}